Dr Bruna Pellini is an Assistant Member at the Department of Thoracic Oncology at Moffitt Cancer Center and Research Institute and an Assistant Professor at Morsani College of Medicine at the University of South Florida. She specializes in the care of patients diagnosed with lung cancer. Dr Pellini received her medical degree from Universidade Federal do Rio Grande do Sul, Brazil and completed her internal medicine residency at University of Central Florida College of Medicine followed by her medical oncology fellowship at Washington University School of Medicine in St. Louis. Her post-doctoral research in Dr Aadel Chaudhuri’s laboratory focused on circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection across different solid tumors. Dr Pellini’s research focuses on liquid biopsies for treatment response monitoring, MRD detection, and their implementation into clinical trials. She also develops and leads clinical trials with novel therapeutics targeting genomic alterations in non-small cell lung cancer with a special focus in KRAS-mutant non-small cell lung cancer. Dr Pellini is a recipient of the Robert A. Winn Diversity in Clinical Trials Career Development Award and is a former scholar of the Cancer Genomics Research STRENGTH Program (R25CA190190). In a national level, she is the co-Chair of the NIH Liquid Biopsy Scientific Interest Group, and a member of the SWOG Lung Translational Medicine Subcommittee.

Dr Bruna Pellini has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bristol Myers Squibb, Regeneron and Merck